Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note published on Monday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on RGLS. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Stock Performance

RGLS stock opened at $1.50 on Monday. The firm has a 50 day moving average price of $1.55 and a 200-day moving average price of $1.81. The firm has a market capitalization of $98.25 million, a price-to-earnings ratio of -1.40 and a beta of 1.63. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, sell-side analysts forecast that Regulus Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RGLS. Creative Planning bought a new position in shares of Regulus Therapeutics in the 3rd quarter worth approximately $26,000. SG Americas Securities LLC bought a new position in Regulus Therapeutics in the third quarter worth approximately $33,000. Rhumbline Advisers purchased a new position in shares of Regulus Therapeutics during the 2nd quarter worth $136,000. Tyche Wealth Partners LLC grew its position in shares of Regulus Therapeutics by 920.6% during the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.